GlassScriptPhysician profile
John O Stanley
NPI 1457358459
$2,038.94
in general payments reported to CMS, 2019-2025
29 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,066 · 2020: $663 · 2021: $311.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $326.78 | 2019-2021 | |
| Amarin Pharma, INC. | $252.37 | 2019-2021 | |
| Pfizer INC. | $236.97 | 2019-2020 | |
| Amgen INC. | $225.25 | 2019-2021 | |
| Novo Nordisk INC | $206.28 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $162.71 | 2019-2020 | |
| Astellas Pharma US INC | $68.00 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $56.52 | 2019-2021 | |
| Abbvie INC. | $51.16 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $46.28 | 2019-2021 | |
| Glaxosmithkline, LLC. | $44.67 | 2019 | |
| Allergan, INC. | $42.04 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $40.57 | 2020-2021 | |
| Merck Sharp & Dohme LLC | $36.89 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $27.17 | 2019-2021 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $26.29 | 2019-2021 | |
| Roche Diagnostics Corporation | $19.53 | 2021 | |
| Ultragenyx Pharmaceutical INC. | $18.15 | 2020 | |
| Upsher-Smith Laboratories LLC | $17.81 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $15.55 | 2019 | |
| Boston Scientific Corporation | $15.18 | 2019 | |
| Daiichi Sankyo INC. | $14.92 | 2019 | |
| Mylan Specialty L.P. | $13.95 | 2021 | |
| Arbor Pharmaceuticals, INC. | $13.30 | 2019 | |
| Lilly USA, LLC | $12.43 | 2019 | |
| Aytu Biopharma, INC. | $12.34 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $12.21 | 2020 | |
| Therapeuticsmd, INC. | $11.89 | 2019 | |
| Scilex Pharmaceuticals INC. | $11.73 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Stanley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.